[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid].
In a 5-year prospective double blind study on 120 diabetics at the age from 30 to 59 years the influence of 1.5 (1.0) g acetyl salicylic acid on the progression of the macro- and microangiopathy compared to a placebo was investigated. With regard to the total mortality, the cardiovascular death rate and the incidence of myocardial infarction, apoplectic insult and gangrene no advantages were the results for the group of intervention. Also the 74 test persons of the acetyl salicyl acid group and 88 test persons of the control group who remained after subtraction of all deceased and dismissed patients in the semiquantitative judgment of the progression of macroangiopathy (ischaemic heart disease, chronic venous insufficiency, arterial occlusive disease, vascular calcification) and in the development of retinopathy no significant differences in the sense of the effect of acetyl salicyl acid expected could be recognized. After the discussion of possible sources of error the result of the investigation is regarded as so reliable that one must dissuade from a primary prevention of the diabetic angiopathy by a middle-term application of acetyl salicyl acid in usual dosage.
D000328:Adult; D001157:Arterial Occlusive Diseases / Q000517:prevention & control; D001241:Aspirin / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control; D003925:Diabetic Angiopathies / Q000401:mortality / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D013927:Thrombosis / Q000517:prevention & control
D001241:Aspirin
5jährige kontrollierte Therapiestudie zur Prophylaxe der diabetischen Angiopathie mit dem Plättchenfunktionshemmer Azetylsalizylsäure.